Becton, Dickinson Aktie 912061 / US0758871091
222.38
USD
0.01
USD
0.00%
16:44:54
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Becton, Dickinson Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2024 | Becton, Dickinson & Co. (BD) | 1.58 | 3.80 | USD |
| 2023 | Becton, Dickinson & Co. (BD) | 1.41 | 3.64 | USD |
| 2022 | Becton, Dickinson & Co. (BD) | 1.56 | 3.48 | USD |
| 2021 | Becton, Dickinson & Co. (BD) | 1.35 | 3.32 | USD |
| 2020 | Becton, Dickinson & Co. (BD) | 1.36 | 3.16 | USD |
| 2019 | Becton, Dickinson & Co. (BD) | 1.22 | 3.08 | USD |
| 2018 | Becton, Dickinson & Co. (BD) | 1.15 | 3.00 | USD |
| 2017 | Becton, Dickinson & Co. (BD) | 1.49 | 2.92 | USD |
| 2016 | Becton, Dickinson & Co. (BD) | 1.47 | 2.64 | USD |
| 2015 | Becton, Dickinson & Co. (BD) | 1.81 | 2.40 | USD |
Gewinn je Aktie- Becton, Dickinson
| 0.6 18 | 3.9 19 | 2.7 20 | 6.8 21 | 5.9 22 | 4.9 23 | 5.9 24 |
Umsatz je Aktie- Becton, Dickinson
| 60.4 18 | 62.9 19 | 60.6 20 | 69.3 21 | 65.7 22 | 67.2 23 | 69.3 24 |
KGV- Becton, Dickinson
| 435 18 | 64.2 19 | 85.7 20 | 35.9 21 | 37.9 22 | 52.4 23 | 40.7 24 |
Becton, Dickinson & Co. (BD): Die Aktie (in USD)
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 0.60 | 3.94 | 2.71 | 6.85 | 5.88 | 4.94 | 5.93 |
| Gewinn je Aktie unverwässert | 0.62 | 4.01 | 2.75 | 6.92 | 5.93 | 4.97 | 5.96 |
| Gewinn je Aktie verwässert | 0.60 | 3.94 | 2.72 | 6.85 | 5.88 | 4.94 | 5.93 |
| Dividende pro Aktie | 3.00 | 3.08 | 3.16 | 3.32 | 3.48 | 3.64 | 3.80 |
| Gesamtdividendenausschüttung in Mio. | 927.00 | 984.00 | 1’026.00 | 1’048.00 | 1’082.00 | 1’114.00 | 1’100.00 |
Becton, Dickinson & Co. (BD): Unternehmenskennzahlen (in USD)
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 60.40 | 62.92 | 60.61 | 69.32 | 65.67 | 67.17 | 69.34 |
| KGV (Jahresendkurs, EPS unverwässert) | 435.00 | 64.20 | 85.67 | 35.86 | 37.91 | 52.36 | 40.66 |
| KGV (Jahresendkurs, EPS verwässert) | 435.00 | 64.20 | 85.67 | 35.86 | 37.91 | 52.36 | 40.66 |
| KGV (Jahresendkurs) | 435.00 | 64.20 | 85.67 | 35.86 | 37.91 | 52.36 | 40.66 |
| Dividendenrendite Jahresende in % | 1.15 | 1.22 | 1.36 | 1.35 | 1.56 | 1.41 | 1.58 |
| Eigenkapitalquote in % | 38.95 | 40.72 | 44.00 | 43.96 | 47.76 | 48.88 | 45.23 |
| Fremdkapitalquote in % | 61.05 | 59.28 | 56.00 | 56.04 | 52.24 | 51.12 | 54.77 |
Becton, Dickinson & Co. (BD): GuV (in Mio. USD)
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 15’983.00 | 17’290.00 | 17’117.00 | 20’248.00 | 18’870.00 | 19’372.00 | 20’178.00 |
| Umsatzveränderung in % | 32.17 | 8.18 | -1.00 | 18.29 | -6.81 | 2.66 | 4.16 |
| Bruttoergebnis vom Umsatz | 7’262.00 | 8’288.00 | 7’577.00 | 9’476.00 | 8’477.00 | 8’170.00 | 9’153.00 |
| Bruttoergebnisveränderung in % | 22.21 | 14.13 | -8.58 | 25.06 | -10.54 | -3.62 | 12.03 |
| Operatives Ergebnis | 2’241.00 | 2’894.00 | 2’156.00 | 3’270.00 | 2’516.00 | 2’196.00 | 2’884.00 |
| Veränderung Operatives Ergebnis in % | 3.32 | 29.14 | -25.50 | 51.67 | -23.06 | -12.72 | 31.33 |
| Ergebnis vor Steuern | 1’173.00 | 1’176.00 | 985.00 | 2’242.00 | 1’783.00 | 1’662.00 | 2’033.00 |
| Veränderung Ergebnis vor Steuern in % | 20.18 | 0.26 | -16.24 | 127.61 | -20.47 | -6.79 | 22.32 |
| Ergebnis nach Steuer | 311.00 | 1’234.00 | 874.00 | 2’092.00 | 1’635.00 | 1’530.00 | 1’726.00 |
| Veränderung Ergebnis nach Steuer in % | -71.73 | 296.78 | -29.17 | 139.36 | -21.85 | -6.42 | 12.81 |
Becton, Dickinson & Co. (BD): Bilanz (in Mio. USD)
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 32’910 | 30’684 | 30’247 | 30’189 | 27’652 | 26’983 | 31’375 |
| Langzeit Gesamtverbindlichk. pro Aktie | 95.79 | 92.55 | 84.17 | 82.83 | 70.02 | 70.05 | - |
| Eigenkapital | 20’994 | 21’081 | 23’765 | 23’677 | 25’282 | 25’797 | 25’911 |
| Veränderung Eigenkapital in % | 62.15 | 0.41 | 12.73 | -0.37 | 6.78 | 2.05 | 0.44 |
| Bilanzsumme | 53’904 | 51’765 | 54’012 | 53’866 | 52’934 | 52’780 | 57’286 |
| Veränderung Bilanzsumme in % | 42.85 | -3.97 | 4.34 | -0.27 | -1.73 | -0.29 | 8.54 |
Becton, Dickinson & Co. (BD): Sonstige Angaben (in USD)
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 0.62 | 4.01 | 2.75 | 6.92 | 5.93 | 4.97 | 5.96 |
| Veränderung Gewinn je Aktie (unverwässert) in % | -86.81 | 546.77 | -31.44 | 151.71 | -14.37 | -16.07 | 19.75 |
| Gewinn je Aktie (verwässert) | 0.60 | 3.94 | 2.72 | 6.85 | 5.88 | 4.94 | 5.93 |
| Veränderung Gewinn je Aktie (verwässert) in % | -86.98 | 556.67 | -31.07 | 152.36 | -14.25 | -15.99 | 20.10 |
| Anzahl Mitarbeiter | 76’032 | 70’093 | 72’000 | 75’000 | 77’000 | 73’000 | - |
| Veränderung Anzahl Mitarbeiter in % | 81.32 | -7.81 | 2.72 | 4.17 | 2.67 | -5.19 | - |
Becton, Dickinson & Co. (BD) Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Becton, Dickinson & Co. (BD) | Quartalszahlen | 06.02.2025 |
| Becton, Dickinson & Co. (BD) | Quartalszahlen | 01.05.2025 |
| Becton, Dickinson & Co. (BD) | Quartalszahlen | 31.07.2025 |
| Becton, Dickinson & Co. (BD) | Quartalszahlen | 06.11.2025 |
| Becton, Dickinson & Co. (BD) | Quartalszahlen | 29.01.2026 |
| Becton, Dickinson & Co. (BD) | Quartalszahlen | 30.04.2026 |
| Becton, Dickinson & Co. (BD) | Quartalszahlen | 30.07.2026 |
| Becton, Dickinson & Co. (BD) | Quartalszahlen | 05.11.2026 |
Becton, Dickinson & Co. (BD) vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q4 2024 Earnings Release | 07.11.2024 |
| Quartalszahlen | Q3 2024 Earnings Release | 01.08.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 02.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 01.02.2024 |
| Hauptversammlung | Annual General Meeting | 23.01.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 09.11.2023 |
| Quartalszahlen | Q3 2023 Earnings Release | 03.08.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 04.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 02.02.2023 |
| Hauptversammlung | Annual General Meeting | 24.01.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 10.11.2022 |
| Quartalszahlen | Q3 2022 Earnings Release | 04.08.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 05.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 03.02.2022 |
| Hauptversammlung | Annual General Meeting | 25.01.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.85 |
| The Vanguard Group, Inc. | 9.04 |
| Vanguard Group, Inc. (Subfiler) | 8.74 |
| State Street Corp. | 4.83 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 4.53 |
| T. Rowe Price Associates, Inc. (IM) | 3.60 |
| Vanguard Total Stock Market ETF | 3.17 |
| T. Rowe Price Investment Management, Inc. | 3.08 |
| BlackRock Fund Advisors | 2.88 |
| Vanguard 500 Index Fund | 2.62 |
| BlackRock Institutional Trust Co. NA | 2.18 |
| Geode Capital Management LLC | 2.17 |
| Morgan Stanley Investment Management Ltd. | 2.08 |
| Generation Investment Management LLP | 2.06 |
| T Rowe Price Capital Appreciation Fund | 2.05 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 72’000 | 75’000 | 77’000 | 73’000 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.24 | 0.27 | 0.25 | 0.27 | 0.00 |
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 8’969 | 8’838 | 8’141 | 8’676 | 10’468 |
| Summe Anlagevermögen | 45’043 | 45’028 | 44’793 | 44’104 | 46’818 |
| Summe Aktiva | 54’012 | 53’866 | 52’934 | 52’780 | 57’286 |
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 18’373 | 18’080 | 16’567 | 16’410 | 20’110 |
| Summe Fremdkapital | 30’247 | 30’189 | 27’652 | 26’983 | 31’375 |
| Summe Eigenkapital | 23’765 | 23’677 | 25’282 | 25’797 | 25’911 |
| Summe Passiva | 54’012 | 53’866 | 52’934 | 52’780 | 57’286 |
Adresse
| 1 Becton Drive, 07417-1880 Franklin Lakes | |
| Telefon | +1 (201) 847-6800 |
| URL | http://www.bd.com |
Management
|
Ami E. Simunovich
Chief Quality & Regulatory Officer, Executive VP |
|
Antoine Ezell
Chief Marketing Officer & EVP-North America |
|
Antoinette F. Segreto
Senior Vice President-Taxes |
|
Bertram L. Scott
Lead Independent Director |
|
Brooke Story
President-Integrated Diagnostic Solutions |
|
Carrie L. Byington
Independent Director |
|
Catherine M. Burzik
Independent Director |
|
Christopher Ian Montague Jones
Independent Director |
|
Christopher J. DelOrefice
Chief Financial & Accounting Officer, EVP |
|
Claire M. Fraser-Liggett
Independent Director |
|
Claudia Curtis
Chief Ethics & Compliance Officer, Senior VP |
|
David Shan
Chief Quality Officer & Executive Vice President |
|
Denise Russell Fleming
Chief Information Officer & EVP-Technology |
|
Ebonee Lewis
Chief Employment Counsel |
|
Elizabeth McCombs
Chief Technology Officer & Executive VP |
|
Gary M. Cohen
President-Global Health & Executive VP |
|
Gary Michael DeFazio
Secretary, Senior VP & Associate General Counsel |
|
Gregory Rodetis
Treasurer, Senior VP & Head-Investor Relations |
|
Jeffrey William Henderson
Independent Director |
|
Joanne Waldstreicher
Independent Director |
|
Joseph M. Smith
Chief Scientific Officer & Senior Vice President |
|
Michael Feld
Executive Vice President & President-Life Sciences |
|
Michelle Quinn
Executive Vice President & General Counsel |
|
Rishi Grover
Chief Integrated Supply Chain Officer & EVP |
|
Robert Andrew Eckert
Independent Director |
|
Ronald P. Silverman
Chief Medical Officer & Executive Vice President |
|
Shana Carol Neal
Chief People Officer & Executive Vice President |
|
Stephen O. Richard
Chief Risk Officer & Senior Vice President |
|
Thomas E. Polen
Chairman, President & Chief Executive Officer |
|
Thomas J. Spoerel
Senior Vice President & Controller |
|
Timothy M. Ring
Independent Director |
|
Vishy Kanda
Chief Strategy Officer & Senior Vice President |
|
William M. Brown
Independent Director |